protein isoform regulates MAP kinase activity and the actin cytoskeleton turnover, which are both required for normal glucose transport responses. To investigate the role of p66
protein isoform regulates MAP kinase activity and the actin cytoskeleton turnover, which are both required for normal glucose transport responses. To investigate the role of p66
Shc in glucose transport regulation in skeletal muscle cells, L6 myoblasts with antisensemediated reduction (L6/p66
Shc as) or adenovirus-mediated overexpression (L6/p66
Shc adv) of the p66 Shc protein were examined. L6/ Shc as myoblasts showed constitutive activation of ERK-1/2 and disruption of the actin network, associated with an 11-fold increase in basal glucose transport. GLUT1 and GLUT3 transporter proteins were sevenfold and fourfold more abundant, respectively, and were localized throughout the cytoplasm. Conversely, in L6 myoblasts overexpressing p66 Shc , basal glucose uptake rates were reduced by 30% in parallel with a ϳ50% reduction in total GLUT1 and GLUT3 transporter levels. Inhibition of the increased ERK-1/2 activity with PD98059 in L6/ Shc as cells had a minimal effect on increased GLUT1 and GLUT3 protein levels, but restored the actin cytoskeleton, and reduced the abnormally high basal glucose uptake by 70%. In conclusion, p66
Shc appears to regulate the glucose transport system in skeletal muscle myoblasts by controlling, via MAP kinase, the integrity of the actin cytoskeleton and by modulating cellular expression of GLUT1 and GLUT3 transporter proteins via ERK-independent pathways.
glucose transporter 1; glucose transporter 3; extracellular signal related kinase SKELETAL MUSCLE IS A MAJOR site of glucose disposal in vivo, and this function is tightly regulated to guarantee efficient glucose uptake and metabolism upon environment-driven changes in energy demand. At the cellular level, transport of glucose across the plasma membrane is the first rate-limiting step for glucose metabolism and is mediated by facilitative glucose transporter (GLUT) proteins, both in skeletal muscle fibers and in cultured skeletal muscle cells (9, 32) . The glucose transport system has been extensively characterized in the rat L6 skeletal muscle cell line (41, 50) . While fully differentiated myotubes express mainly GLUT1 and GLUT4, accounting for basal and hormone-stimulated glucose uptake, respectively (11, 31) , L6 myoblasts express mainly GLUT1, which is ubiquitous, and GLUT3, which is typically found in fetal (15) and regenerating muscle (11) , as well as in neuronal cells (25) . In the absence of hormonal stimulation, in L6 myoblasts, GLUT1 is uniformly localized to both the plasma membrane and an intracellular pool of specialized vesicles, whereas GLUT3 is mainly intracellular (11) . Regulation of the cellular content and localization of GLUT1 and/or GLUT3, leading to increased glucose transport activity, represents an adaptive response to the increased energy demand associated with various external stimuli, including exposure to insulin or IGF-I (19, 20, 32) , hypoxia (2, 54) , and oxidative stress (14, 21, 40) . Even though distinct protein members of the MAP kinase family were found to affect the expression of various GLUT proteins in different experimental conditions (13, 46, 53) , the signaling events regulating the glucose transport system in myoblasts remain to be completely clarified.
The p66 Shc protein is one of the three isoforms encoded by the mammalian Shc locus (38) . All three isoforms can be tyrosine phosphorylated upon growth factor stimulation; however, p46/p42
Shc is coupled to growth and survival signals, whereas p66
Shc also undergoes serine phosphorylation and inhibits activation of the MEK/MAP kinase pathway triggered by growth factor receptors (30, 33, 34) . In addition, p66
Shc has been proposed as a cellular mediator of oxidative stress, and this response appears to regulate proapoptotic signals and life span in mammals (29, 36) . We (33) have shown that selective reduction of p66
Shc in L6 myoblasts resulted in constitutive activation of the MEK/MAP kinase signaling pathway, leading to complete disruption of the actin network, which is critical for the maintenance of cell shape and intracellular trafficking. Indeed, both MAP kinase activity and the actin network regulate the glucose transport system. Transfection of constitutively active mutants of MEK into 3T3-L1 adipocytes resulted in increased basal glucose transport activity associated with increased expression of GLUT1 mRNA and protein (53) ; furthermore, IGF-I-induced glucose transport in retinal endothelial cells requires activation of MAP kinase (6) . On the other hand, several studies have shown that cellular glucose transport in insulin-sensitive cells relies on the integrity of the actin and microtubule cytoskeleton. Treatment of L6 myotubes, 3T3-L1 adipocytes, or rat adipocytes with specific cytoskeleton disrupters, such as cytochalasin D or latrunculin A, resulted in marked inhibition of insulin-mediated GLUT4 translocation (35, 49, 51) .
In this study, we investigated the role of p66
Shc on glucose uptake and glucose transporter expression and localization in L6 myoblasts. We show that p66
Shc plays an important role in the regulation of cellular glucose uptake by 1) conveying MAP kinase-dependent signals to the actin network, which ultimately affects glucose transporter trafficking; and 2) modulating expression of GLUT1 and GLUT3 transporter proteins in skeletal muscle cells.
MATERIALS AND METHODS
Cell cultures and antibodies. L6 rat skeletal muscle myoblasts were cultured in MEM supplemented with 10% BCS (both from Invitrogen, Carlsbad, CA), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and nonessential amino acids in a 5% CO2 atmosphere at 37°C. To block the MEK/ERK signaling pathway, cells were incubated with 20 M PD98059 (Calbiochem, Merck, Darmstadt, Germany) for the indicated times. To disassemble actin cytoskeleton, cells were incubated with 2 M cytochalasin D (Sigma, St. Louis, MO) for 1 h.
Polyclonal GLUT1 and GLUT3 antibodies were purchased from Chemicon (Temecula, CA). Polyclonal Shc antibodies were from Transduction Laboratories (Lexington, KY). Anti-MAP kinase (ERK-1/2) antibodies were obtained from Zymed Laboratories (San Francisco, CA). Anti-phospho-p42/44 MAP kinase (ERK-1/2; Thr 202 / Tyr 204 ) was obtained from New England Biolabs (Beverly, MA). Anti-GAPDH(FL-335) was from Santa Cruz Biotechnology (Santa Cruz, CA).
Transfection studies. L6 myoblasts stably expressing reduced levels of the p66
Shc protein isoform were generated as previously described (33) . Briefly, plasmids containing p66
Shc -specific oligonucleotides in antisense orientation were transfected into L6 myoblasts by liposome-mediated gene transfer using Lipofectamine (Invitrogen, Carlsbad, CA). Efficient p66 Shc overexpression was confirmed by PCR amplification of the integrated plasmid and by immunoblotting of total cell lysates with Shc antibodies (33) .
To generate L6 myoblasts expressing augmented levels of the p66 Shc protein, the gene of interest was first cloned into a shuttle vector pAdTrack-CMV containing a green fluorescent protein epitope. The resultant plasmid was linearized by digesting with restriction endonuclease PmeI and subsequently was cotransformed into Escherichia coli BJ5183 cells with an adenoviral backbone plasmid pAdEasy-1. Recombinants were selected for kanamycin resistance, and recombination was confirmed by restriction endonuclease analyses. Finally, the recombinant plasmid was linearized by digesting with restriction endonuclease PacI and then transfected into the adenovirus packaging cell line QBI293A. Scalar doses of adenovirus-containing culture medium were used to biologically define the optimal infection dose (Ͼ90% of infected cells) for L6 myoblasts.
Glucose transport assay. Transport activity was determined in cells cultured in 35-mm diameter wells. After incubation in serum-free MEM for 16 h, cells were washed twice with 2 ml of buffer A (140 mM NaCl, 2.5 mM MgCl2, 1 mM CaCl2, 5 mM KCl, and 20 mM HEPES, pH 7.4) at 37°C, and transport was started by adding 2-[ 3 H]deoxy-D-glucose (NEN, Boston, MA), 1 Ci in 1 ml of buffer A, to a concentration of 50 M for 10 min at 20°C. Transport was stopped by placing the cells on ice and rapidly washing them three times with ice-cold buffer A. Cells were lysed in 1 ml 0.05 N NaOH for 45 min. Aliquots of this lysate were used for liquid scintillation counting and determination of protein content. Nonspecific transport was determined by performing the assay in the presence of 10 M cytochalasin B.
Cell fractionation. To isolate total cellular membranes, L6 skeletal muscle cells were collected into 5 ml of ice-cold HES buffer (250 mM sucrose, 1 mM EDTA, 1 mM PMSF, 1 M pepstatin, 1 M aprotinin, 1 M leupeptin, 20 mM HEPES, pH 7.4) and subsequently homogenized with 20 strokes in a glass Dounce homogenizer (Type C; Thomas, Philadelphia, PA) at 4°C. After centrifugation at 1,000 g for 3 min at 4°C to remove large cell debris and unbroken cells, the supernatant from this first spin was separated from the pellet and then centrifuged at 245,000 g for 90 min at 4°C to yield a pellet of total cellular membranes (31, 50) .
Immunoblotting. For preparing total cell lysates, L6 skeletal muscle cells were washed with Ca 2ϩ /Mg 2ϩ -free PBS and then mechanically detached in ice-cold lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM MgCl 2, 1 mM CaCl2, 10% glycerol, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 2 mM EDTA, 2 mM PMSF, 5 g/ml leupeptin, 2 mM sodium orthovanadate, and 1% Nonidet P-40. Cell lysates were then centrifuged at 12,000 g for 10 min, and the resulting supernatant was collected and assayed for protein concentration using the Bradford dye binding assay kit with BSA as a standard. For immunoblotting studies, equal amounts of cellular proteins were resolved by electrophoresis on 10% SDSpolyacrylamide gels. The resolved proteins were electrophoretically transferred to nitrocellulose membranes (Hybond-ECL; Amersham Life Science, Arlington Heights, IL) using a transfer buffer containing 192 mM glycine, 20% (vol/vol) methanol, and 0.02% SDS. To reduce nonspecific binding, the membranes were incubated in TNA buffer (10 mM Tris ⅐ HCl, pH 7.8, 0.9% NaCl, and 0.01% sodium azide) supplemented with 5% BSA and 0.05% Nonidet P-40 for 2 h at 37°C, or in PBS supplemented with 3% nonfat dry milk for 2 h at room temperature, as appropriate, and then incubated overnight at 4°C with the indicated antibodies. The proteins were visualized by enhanced chemiluminescence using horseradish peroxidase-labeled anti-rabbit or anti-mouse IgG (Amersham Life Science) and quantified by densitometric analysis using Quantity One image analysis software (BioRad Laboratories, Hercules, CA).
Immunofluorescence analyses. To visualize the actin cytoskeleton, L6 cells were grown on coverslips in complete medium in the absence or presence of 20 M PD98059 for 72 h and/or 2 M cytochalasin D for 1 h, as indicated, and then they were fixed with 4% paraformaldehyde and permeabilized with PBS supplemented with 0.1% Triton X-100. Fixed cells were incubated with FITC-conjugated phalloidin Oregon Green 514 or tetramethyl rhodamine isothiocyanate-conjugated phalloidin (Molecular Probes, Eugene, OR) for 20 min and subsequently washed three times with PBS. Coverslips were mounted on glass slides with gel mount (Biomeda, Foster City, CA). Pictures were acquired on a Leica TCS SP2 laser scanning spectral confocal microscope (Leica Microsystems, Heerbrugg, Switzerland), and all images were taken at the same magnification.
To study the intracellular localization of GLUT1 and GLUT3, L6 cells were grown on glass coverslides and incubated in the absence or presence of 20 M PD98059 for 72 h and/or 2 M cytochalasin D for 1 h, as indicated. Cells were fixed with 4% paraformaldehyde, permeabilized with PBS supplemented with 0.1% Triton X-100 for 15 min, and then incubated with polyclonal GLUT1 or GLUT3 antibodies in PBS-3% BSA (1:100) overnight at 4°C. Cells were then washed three times with PBS and incubated with Alexa Fluor 488 anti-rabbit antibodies in PBS (1:500) for 180 min at 25°C.
Measurements of GLUT1 and GLUT3 mRNAs by quantitative RT-PCR. Total RNA was isolated from L6 cells using RNeasy mini kit (Qiagen, Hilden, Germany). Genomic DNA contamination was eliminated by DNase digestion (Qiagen), and 1 g of total RNA was used for cDNA synthesis using QuantiTect reverse transcription kit (Qiagen). GLUT1, GLUT3, and rRNA 18S primers were designed using Primer Express 3.0 (Applied Biosystems) as follows: glut1-For: 5Ј-GCATCGTCGTTGGGATCCT-3Ј; glut1-Rev: 5Ј-CAAGTCTGCATTGCCCATGA-3Ј; glut3-For: 5Ј-GGCTCTTTT-TCTGTCGGACTCTT-3Ј; glut3-Rev: 5Ј-AAGGATGGCAATCAG-GTTGACT-3Ј; 18S-For: 5Ј-TGATTAAGTCCCTGCCCTTTGT-3Ј; and 18S-Rev: 5Ј-GATCCGAGGGCCTCACTAAAC-3Ј. The PCR reactions were carried out in an ABI PRISM 7500 System (Applied Biosystems) under the following conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for 1 min. Relative RNA levels were determined by analyzing the changes in SYBR green fluorescence during PCR using the ⌬⌬CT method. To confirm amplification of specific transcripts, melting curve profiles were produced at the end of each reaction. The mRNA levels of GLUT1 and GLUT3 were normalized using rRNA 18S as an internal control.
Statistical analyses. All data are expressed as means Ϯ SE. Data are expressed as percentage of control values. P values of Ͻ0.05 were considered to represent statistical significance. Statistical analyses were performed by unpaired Student's t-tests or one-way ANOVA tests, as appropriate.
RESULTS

Glucose transport in myoblasts with reduced p66
Shc . To investigate the potential role of p66
Shc in the regulation of the glucose transport system, basal glucose uptake was analyzed in three independent clones of L6 myoblasts with antisensemediated reduction of p66
Shc protein levels (L6/p66 Shc as myoblasts, clones C6, D27, and D28; Fig. 1A ). In the L6/p66
Shc as myoblasts, p66
Shc protein levels were decreased by ϳ90% compared with untransfected wild-type L6 myoblasts or L6/ Neo myoblasts transfected with the empty pCR3.1 vector (L6/Neo and clones N1 and N5; P Ͻ 0.05), while the protein levels of the other Shc isoforms, i.e., p52
Shc and p46 Shc , were not significantly altered (Fig. 1A) . Expression levels of the housekeeping protein GAPDH were also similar in L6, L6/ Neo, and L6/p66
Shc as myoblasts (Fig. 1A) . Noteworthy, basal 2-[ 3 H]deoxy-D-glucose uptake was found to be markedly higher, by ϳ11-fold, in L6/p66
Shc as compared with untransfected L6 and L6/Neo cells (P Ͻ 0.05; Fig. 1B) .
The p66 Shc protein exerts an inhibitory effect on the MEK/ MAP kinase signaling pathway, and thus L6 myoblasts with selective reduction of p66
Shc show markedly increased basal levels of ERK-1/2 phosphorylation (33). To assess whether the constitutive activation of MEK/MAP kinase could contribute to the observed glucose transport changes in L6/p66
Shc as myoblasts, basal glucose uptake was assessed after exposure of cells to the MEK inhibitor PD98059 for 72 h. The elevated levels of basal ERK-1/2 phosphorylation, observed in L6/ p66
Shc as myoblasts, were markedly reduced by PD98059, and thus after treatment with this compound, ERK-1/2 phosphorylation was similarly low in L6/p66 Shc as and control myoblasts ( Fig. 2A) . In control cells, basal glucose uptake was not affected by pretreatment of cells with the MEK inhibitor (Fig.  2B) . By contrast, in L6/p66 Shc as myoblasts, treatment with PD98059 resulted in a 50% reduction of the high basal glucose transport (P Ͻ 0.05 vs. untreated L6/p66
Shc as cells; Fig. 2B ); however, glucose transport was still fourfold higher in PD98059-treated L6/p66
Shc as myoblasts compared with control cells (P Ͻ 0.05; Fig. 2B ).
Glucose transporters in myoblasts with reduced p66 Shc . To investigate whether the enhanced basal glucose transport in L6/ Shc as myoblasts could be explained by p66 Shc -related changes in the amounts of glucose transporters, the protein levels of GLUT1 and GLUT3, the two predominant glucose transporter protein isoforms expressed in L6 myoblasts, were measured in total cellular membranes by immunoblotting with GLUT1 or GLUT3 antibodies, respectively. GLUT4 was not analyzed because its expression is very low in the myoblast stage of L6 cells, and it undergoes significant augmentation when they differentiate into myotubes (11, 31) . GLUT1 protein levels were sevenfold higher in L6/p66
Shc as compared with wild-type L6 and L6/Neo myoblasts (P Ͻ 0.05; Fig. 3A) . Similarly, L6/p66
Shc as myoblasts showed a fourfold increase in GLUT3 protein content compared with control cells (P Ͻ 0.05; Fig. 3B ). To assess whether the changes in glucose Fig. 1 transporter protein abundance could result from increased gene expression, GLUT1 and GLUT3 mRNA levels were evaluated. GLUT1 mRNA levels were threefold higher in L6/p66
Shc as compared with L6/Neo myoblasts (P Ͻ 0.05; Fig. 3C ). Similarly, L6/p66
Shc as myoblasts showed a twofold increase in GLUT3 mRNA levels compared with control cells (P Ͻ 0.05; Fig. 3D ). Whether the constitutive activation of MEK/MAP kinase could contribute to the increased glucose transporter protein levels in L6/p66
Shc as myoblasts was investigated next. However, treatment with PD98059 had no effect on GLUT1 protein levels in control cells and did not significantly reduce GLUT1 in L6/p66
Shc as myoblasts (679 vs. 764% of control; P ϭ 0.3; Fig. 4A presence and absence of the MEK inhibitor in both control and L6/p66
Shc as myoblasts (Fig. 4B) .
Integrity of the actin cytoskeleton and regulation of the glucose transport system. Constitutive activation of ERK-1/2 in the basal state in L6/p66
Shc as myoblasts results in abnormalities of the cell morphology due to disruption of actin fibers and cytoskeleton (33) , and this could potentially affect the intracellular distribution of glucose transporters and overall glucose transport activity. In control myoblasts, in which actin fibers could be easily detected (Fig. 5, A and B) , GLUT1 appeared to be uniformly distributed in the perinuclear region (Fig. 5A) . By contrast, L6/p66
Shc as myoblasts showed complete disassembly of the actin network (Fig. 5, A and B) and large amounts of cellular GLUT1, which appeared to completely fill the reduced cell cytoplasm (Fig. 5A) . Similarly, the GLUT3 signal appeared to be localized in the perinuclear region in control cells (Fig. 5B) , and it showed an intense localization throughout the cytosol of the L6/p66
Shc as myoblasts (Fig. 5B) . Inhibition of the MEK/MAP kinase pathway with PD98059 resulted in restoration of the actin cytoskeleton in the L6/p66
Shc as myoblasts (Fig. 5, A and B) ; this was associated with partial relocalization of GLUT1 and GLUT3 transporters, which appeared to be distributed in the perinuclear region and more diffusely along the actin filaments, similar to the control myoblasts. Therefore, in L6 myoblasts with reduced p66
Shc levels, the increased basal glucose uptake was associated with increased protein content as well as disruption of the actin cytoskeleton, possibly resulting in altered cellular localization of GLUT1 and GLUT3 glucose transporters. Inhibition of the constitutive activation of ERK-1/2 in the L6/p66 Shc as myoblasts did not significantly reduce the abnormally elevated levels of GLUT1 and GLUT3 glucose transporters but partially corrected the increase in glucose transport, likely through reorganization of the actin network.
To verify whether the integrity of the actin cytoskeleton is indeed essential for the appropriate regulation of the glucose transport system in rat myoblasts, control L6 cells were studied after incubation with the actin-disrupting agent cytochalasin D, which provoked a marked disorganization of the actin network (Fig. 6A) . Treatment with cytochalasin D also induced a change in the cellular localization of both GLUT1 and GLUT3, which appeared to completely fill up the cytoplasm (Fig. 6A) , similar to what was observed in the L6/p66
Shc as myoblasts (Fig. 6B) , and an augmentation of basal glucose transport rates by 1.5-fold (P Ͻ 0.05; Fig. 6C ). Thus inhibition of actin polymerization partially replicated the effects of p66
Shc reduction on the glucose transport system. To further confirm the role of the actin cytoskeleton in glucose transport regulation in the L6/p66
Shc as myoblasts, glucose uptake was also assessed in these cells after exposure to either the MEK inhibitor PD98059, cytochalasin D, or both of these compounds (Fig.  6D) . Glucose uptake was reduced by 50% after ERK inhibition (P Ͻ 0.05) but remained unaltered when cells were incubated in the presence of cytochalasin D ( Fig. 6D ; P ϭ 0.35 vs. untreated L6/p66
Shc as myoblasts). Importantly, the addition of cytochalasin D to PD98059-treated cells resulted in a significant increase in glucose transport rates (P Ͻ 0.05), which were not different than those of untreated cells (Fig. 6D) . Therefore, the integrity of the actin cytoskeleton is essential for the regulation of the glucose transport system, and changes in glucose transport rates in myoblasts with reduced p66
Shc levels occur, at least in part, via ERK-mediated disassembly of the cytoskeleton integrity.
Glucose transport system in myoblasts with increased p66
Shc . To confirm the involvement of p66 Shc in the regulation of the glucose transport system in rat skeletal muscle cells, L6 myoblasts were examined after overexpression of p66
Shc with a specific recombinant adenoviral vector (L6/p66
Shc adv myoblasts). The adenovirus-mediated p66
Shc gene transfer resulted in an eightfold increase of p66
Shc protein levels compared with noninfected or mock-infected control cells (P Ͻ 0.05; Fig. 7A ).
L6/p66
Shc adv myoblasts showed normal cellular morphology and appeared to grow as a typical monolayer of elongated cells, similar to control cells (Fig. 7B) . In addition, both the actin cytoskeleton and basal ERK phosphorylation appeared to be unchanged in L6 myoblasts overexpressing p66
Shc compared with control cells (Fig. 7C, and data not shown) .
Basal glucose uptake was reduced by ϳ20% in L6/ p66
Shc adv compared with control noninfected and mock-infected L6 myoblasts (P Ͻ 0.05; Fig. 7D ). To evaluate whether the reduced glucose transport rates in L6 myoblasts with augmented p66
Shc levels were associated with altered glucose transporter proteins, the protein levels of GLUT1 and GLUT3 transporters were measured in total cellular membranes by immunoblotting with specific antibodies. GLUT1 protein was found to be significantly reduced in L6/p66
Shc adv compared with control myoblasts (P Ͻ 0.05; Fig. 7E ). In addition, GLUT3 protein levels were markedly lower than control in p66
Shc -overexpressing cells (P Ͻ 0.05; Fig. 7F ). Therefore, in L6 myoblasts, overexpression of p66
Shc results in changes in the glucose transport system, including lower basal transport and decreased protein levels of GLUT1 and GLUT3 transporters, that are opposite to those observed when p66
Shc is knocked down. Shc as (D28) cells were grown on glass slides in complete medium to ϳ80% confluence and then incubated with (ϩ) or without (Ϫ) 20 M PD98059 for 72 h, as indicated. Cells were fixed and then incubated with GLUT1 or GLUT3 antibodies (green), as described in MATERIALS AND METHODS. TO-PRO-3 (blue) and FITC-phalloidin (red) were used to visualize the nuclei and actin cytoskeleton, respectively. Images represent 3 experiments.
DISCUSSION
The p66
Shc protein isoform has been shown to regulate cellular apoptosis and survival (29, 36) , the cytoskeleton architecture (33) , and cellular responses to oxidative stress (29, 36) . In this study, we provide evidence for an important role of p66
Shc in the regulation of glucose uptake in rat skeletal muscle cells. Antisense-mediated reduction of p66
Shc protein content in L6 myoblasts resulted in markedly increased glucose transport (Fig. 1) . Conversely, in p66
Shc -overexpressing L6 cells, basal glucose uptake was reduced (Fig. 7) . These data, for the first time, establish a link between p66
Shc and glucose metabolism in insulin-sensitive cells.
The absolute cellular levels of glucose transporters are critical determinants of the efficiency of the glucose transport system in L6 myoblasts (18) . In previous work (39, 53) , overexpression of GLUT1 in both L6 myoblasts and 3T3-L1 adipocytes was associated with markedly increased basal glucose transport rates, similar to the results of this study. GLUT1 and GLUT3 expression was found to be markedly increased in cells with selective reduction of p66 Shc (Fig. 3) and significantly decreased in p66
Shc -overexpressing myoblasts (Fig. 7) . This directly relates to changes in basal glucose transport, which was increased in L6/p66
Shc as (Fig. 1 ) and decreased in L6/p66
Shc adv cells (Fig. 7) . Signaling through the MEK/MAP kinase pathway has been shown to control GLUT gene expression (53) , and L6/p66 Shc as myoblasts have constitutive activation of the MEK/ERK pathway (33; this study). However, inhibition of the elevated levels of ERK-1 and ERK-2 phosphorylation in L6/p66 Shc as myoblasts did not significantly modify GLUT1 or GLUT3 proteins levels (Fig. 4) . It is possible that MEK inhibition achieved with PD98059 for 72 h was still not sufficient to restore ERK to normal activity levels and/or to allow degradation of excess transporter proteins, which are characterized by relatively long half-lives (16, 42) . However, these results suggest that other p66 Shc -related but ERK-independent signals may be required for the regulation of GLUT gene expression. The observation that GLUT1 and GLUT3 transporters were downregulated while basal ERK activity was not apparently altered in p66
Shc -overexpressing myoblasts ( Fig. 7; Supplemental Figs. 1 and 2 ; supplemental data for this article are available online at the Am J Physiol Endocrinol Metab website) supports the latter hypothesis. It has been recently reported (45) that GLUT1 and GLUT4 promoters are inhibited by the tumor suppressor protein p53 and that point mutations in p53 either partially or completely abolish its inhibitory effects on GLUT1 and GLUT4 gene expression. This may explain the increase in glucose transporter expression associated with certain varieties of cancer characterized by loss of p53 function (45) . Since ablation of p66
Shc is associated with impaired p53-dependent apoptosis (47), it will be important to investigate whether the p66 Shc protein may affect glucose transporter expression via p53 signaling. Other intracellular kinases, such as p70S6 kinase and p38 MAP kinase, have been also implicated in the regulation of glucose transporter expression in L6 myoblasts (13, 46) . Whether these other signaling components may be modulated by p66
Shc has not been yet determined. In the L6 myoblasts with reduced p66
Shc , constitutive activation of MEK/MAP kinase signaling results in disorganization of the actin cytoskeleton (33; this study) and altered subcellular localization of GLUT1 and GLUT3 (Fig. 5) . The Shc proteins have been shown to promote cytoskeleton rearrangement in response to growth factor stimulation through the ERK pathway in multiple cell types (10, 22) . In addition, the p46 Shc and p52 Shc isoforms bind to and are tyrosine phosphorylated by integrin-activated tyrosine kinases, such as FAK and Src (43, 44) , and similarly promote ERK activation. Thus growth factor-and integrin-triggered signals converge on the Shc/ERK pathway and dynamically regulate actin fiber assembly, together with signals transduced through the FAKp130Cas complex. The link between ERK and the cytoskeleton is also demonstrated by the finding that activated ERK can directly phosphorylate and activate myosin light chains and subsequently promote the cytoskeletal contraction necessary for cell movement (17) . In line with these observations, upregulation of MEK activity in rat kidney cells causes disruption of the actin cytoskeleton through MEK-dependent inhibition of the Rho-ROCK-LIM kinase pathway, which promotes actin stress fiber stabilization and actomyosin-based cell contractility (37) . Similarly, in this study, persistent upregulation of ERK activity was found to be inappropriate for maintenance of normal organization of the actin cytoskeleton in L6/p66
Shc as myoblasts; conversely, inhibition of the abnormally elevated MEK/ERK activity with the MEK-inhibitor PD98059 restored Shc adv myoblasts (filled bar). 2-DG uptake was measured as described in MATERIALS AND METHODS. Values are means Ϯ SE of 3 independent experiments performed in triplicate. E and F: total cellular content of GLUT1 and GLUT3 glucose transporters. Wild-type L6 (open bars), L6/Mock (gray bars), and L6/p66
Shc adv (filled bars) myoblasts were grown in complete medium to ϳ90% confluence. Then, total membranes were obtained and analyzed by immunoblotting with GLUT1 (E) or GLUT3 (F) antibodies, as indicated. A representative immunoblot (left) and the quantification of 3 independent experiments (right) are shown. *P Ͻ 0.05 vs. control (L6 and L6/Mock) cells.
the actin network and cell phenotype and was also associated with a 50 -75% reduction of the abnormally high basal glucose uptake (Fig. 2) . This may be explained by the fact that an intact actin cytoskeleton is necessary for intracellular localization and appropriate plasma membrane insertion of glucose transporters (23, 48) . Multiple proteins have been reported to interact with glucose transporters and the actin fibers, providing the molecular scaffold for cytoskeleton-regulated glucose transporter localization and trafficking; these include ␣-actinin-4 (7), SNAP23 (8) , and Enigma (1) and small GTPases such as Ras, Rad, Rho, Arf, and Rab isoforms (4) .
Indeed, the results of this study suggest that basal glucose uptake in rat myoblasts is more strictly dependent on the integrity of the actin network than on the absolute levels of glucose transporter proteins. In control L6 myoblasts, disruption of the cytoskeleton with cytochalasin D was associated with abnormal intracellular localization of GLUT1 and GLUT3 and significantly increased glucose transport rates (Fig. 6 ). In cells with reduced p66
Shc levels treated with the MEK inhibitor, restoration of the actin cytoskeleton markedly reduced the high glucose uptake (Fig. 2) , whereas if the actin network was maintained in a disrupted state by simultaneous incubation with cytocalasin D, the increased glucose uptake rates remained elevated (Fig. 6) . Conversely, in cells with increased cellular levels of p66 Shc , the actin network did not appear to be perturbed and changes in glucose transport rates were rather modest (Fig. 7) . L6 myoblasts with reduction of p66
Shc and overactivation of MEK/ERK signaling exhibited a transformed phenotype, with rounded shape; complete disruption of the actin stress fibers, focal adhesions, and cell cytoskeleton (33) ; and resistance to stress-induced apoptosis (Natalicchio A. and Giorgino F., unpublished results). Importantly, in human breast cancer tissues, a relative reduction in p66
Shc protein levels, leading to a high p46
Shc /p52 Shc -to-p66 Shc expression ratio, correlates with increased proliferative activity and poor prognosis (5) . Interestingly, the abnormalities in the glucose transport system observed in p66
Shc as cells also evoke some features of cancer cells. Tumorigenesis is associated with enhanced cellular uptake and metabolism of glucose, which is required for adaptation to higher energy supply (12) . Increased glucose transport in transformed cells has been associated with increased and deregulated expression of glucose transporter proteins, mainly GLUT1 and/or GLUT3 (3, 26 -28, 52 ). In addition, oncogenic transformation of cultured mammalian cells causes a rapid increase of glucose transport and GLUT1 expression, due to specific effects involving GLUT1 promoter enhancer elements (24) . Induction of the GLUT1 isoform is therefore instrumental in cellular adaptation to stress conditions, including cancer, in which energy requirements are increased (21) . In future work, it will be important to determine whether changes in cellular p66
Shc levels may contribute to the increase in glucose transporter expression and glucose uptake observed in transformed cells.
In conclusion, the p66 Shc protein exerts a constitutive inhibitory effect on ERK-1/2 activity, which is required for appropriate regulation of actin cytoskeleton turnover controlling the normal cellular localization of GLUT1 and GLUT3 in skeletal muscle myoblasts. Loss of p66
Shc results in constitutive activation of ERK-1/2, leading to altered cell cytoskeleton and profound modifications of the cellular glucose uptake capacity. In addition, via other yet unidentified pathways, p66
Shc modulates the cellular levels of GLUT1 and GLUT3, and this also contributes to the changes in glucose uptake. Thus the p66
Shc may represent an effector of glucose transport in skeletal muscle cells and prove to play an important role in the adaptive responses to environmental factors.
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